Payment overview · 2025
General Payments
$276.80
14 reported records · 6 companies
Healthcare provider profile · identity verified
Gary Reed Brouillette, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · MARSHALL, TX · NPI 1780044834
Verified facts
What the public records show
CMS Open Payments records show Gary Reed Brouillette, FNP received $276.80 in general payments during 2025 across 14 reported records.
GlaxoSmithKline, LLC. accounted for 30.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Trelegy Ellipta, Ubrelvy, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $84.81 | 30.6% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $64.87 | 23.4% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $60.17 | 21.7% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $34.06 | 12.3% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.41 | 6.7% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $14.48 | 5.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $276.80 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $67.11 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $44.67 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $44.67 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $41.83 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $34.06 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $34.06 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $20.20 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.41 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.41 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $18.34 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.70 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $14.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 79 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
56 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
79 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
37 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 481 | 141 |
| Amlodipine Besylate | Amlodipine Besylate | 360 | 105 |
| Losartan Potassium | Losartan Potassium | 271 | 76 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 264 | 85 |
| Gabapentin | Gabapentin | 264 | 67 |
| Potassium Chloride | Potassium Chloride | 259 | 86 |
| Lisinopril | Lisinopril | 251 | 64 |
| Montelukast Sodium | Montelukast Sodium | 250 | 78 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 241 | 66 |
| Levothyroxine Sodium | Levothyroxine Sodium | 202 | 48 |
| Metoprolol Tartrate | Metoprolol Tartrate | 201 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 199 | 62 |
| Furosemide | Furosemide | 192 | 62 |
| Hydrochlorothiazide | Hydrochlorothiazide | 190 | 57 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 173 | 53 |
| Omeprazole | Omeprazole | 173 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 169 | 54 |
| Pioglitazone Hcl | Pioglitazone Hcl | 157 | 46 |
| Meloxicam | Meloxicam | 146 | 37 |
| Metformin Hcl | Metformin Hcl | 138 | 46 |
| Celecoxib | Celecoxib | 122 | 34 |
| Metformin Hcl Er | Metformin Hcl | 111 | 34 |
| Trazodone Hcl | Trazodone Hcl | 106 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 101 | 23 |
| Alprazolam | Alprazolam | 97 | 14 |
| Sertraline Hcl | Sertraline Hcl | 96 | 19 |
| Fenofibrate | Fenofibrate,micronized | 87 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 87 | 30 |
| Carvedilol | Carvedilol | 85 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 85 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 84 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 84 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 83 | 28 |
| Amitriptyline Hcl | Amitriptyline Hcl | 81 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 79 | 16 |
| Glimepiride | Glimepiride | 79 | 25 |
| Prednisone | Prednisone | 79 | 63 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 79 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 77 | 18 |
| Allopurinol | Allopurinol | 65 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 63 | 23 |
| Ropinirole Hcl | Ropinirole Hcl | 63 | 16 |
| Buspirone Hcl | Buspirone Hcl | 62 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 62 | 21 |
| Risperidone | Risperidone | 62 | suppressed |
| Spironolactone | Spironolactone | 61 | 15 |
| Eliquis | Apixaban | 59 | 17 |
| Clonidine Hcl | Clonidine Hcl | 58 | 19 |
| Farxiga | Dapagliflozin Propanediol | 56 | 17 |
| Benztropine Mesylate | Benztropine Mesylate | 55 | suppressed |
| Azithromycin | Azithromycin | 52 | 48 |
| Pravastatin Sodium | Pravastatin Sodium | 52 | 15 |
| Megestrol Acetate | Megestrol Acetate | 51 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 49 | 17 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 47 | suppressed |
| Glipizide | Glipizide | 47 | 14 |
| Clindamycin Hcl | Clindamycin Hcl | 46 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 46 | 18 |
| Verapamil Er | Verapamil Hcl | 45 | 11 |
| Aripiprazole | Aripiprazole | 43 | suppressed |
| Lorazepam | Lorazepam | 43 | suppressed |
| Simvastatin | Simvastatin | 42 | 13 |
| Clonazepam | Clonazepam | 41 | suppressed |
| Nifedipine Er | Nifedipine | 41 | suppressed |
| Olanzapine | Olanzapine | 41 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 39 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 39 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 37 | 14 |
| Jardiance | Empagliflozin | 37 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 37 | 32 |
| Famotidine | Famotidine | 33 | suppressed |
| Ozempic | Semaglutide | 32 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 31 | suppressed |
| Atenolol | Atenolol | 31 | suppressed |
| Vraylar | Cariprazine Hcl | 31 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | 18 |
| Amoxicillin | Amoxicillin | 28 | 27 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 27 | suppressed |
| Ezetimibe | Ezetimibe | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 24 |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Levofloxacin | Levofloxacin | 24 | 21 |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 23 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 20 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 18 |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Trulicity | Dulaglutide | 19 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | 15 |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Clotrimazole | Clotrimazole | 16 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 14 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Xifaxan | Rifaximin | 13 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 13 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Permethrin | Permethrin | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Acetazolamide | Acetazolamide | 11 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Caplyta | Lumateperone Tosylate | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Ubrelvy | Ubrogepant | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $276.80 · 14 records | GlaxoSmithKline, LLC. | AIRSUPRA, BREZTRI, MOUNJARO, OTEZLA, QULIPTA, REPATHA, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, YUPELRI, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error